What you get

Regardless the solid cancer type, every single report is made by our proprietary algorithms that are browsing public databases and combined with our multi-year expertise in cancer genomics to generate specific insights on your data. All data are curated and validated by our expert scientists before being published in a comprehensive report including:



1. CLINICAL DATA
2. ACTIONABLE VARIANTS INTERPRETATION AND PRIORITISATION
3. DRUGS RECOMMENDATIONS
4. CLINICAL TRIALS
5. ACTIONABLE VARIANTS DETAILS
6. THERAPIES BY CLINICAL IMPACT

READY FOR TUMOUR BOARD!

CERTIFICATIONS

EUROPEAN DATA STORAGE

OncoKDM® evolves in a European data healthcare environment meaning that all medical, personal and processed data are stored and managed to be compliant with the EU 2016/679 General Data Protection Regulation (GDPR).

ISO 13485:2016

OncoKDM® is in the scope of our ISO 13485:2016 certification. This ISO standard specifies the requirements for quality management systems (QMS) in the medical device industry. Being certified indicates that the OncoKDM® quality management system meets the applicable regulatory and customer requirements in the field of medical devices.

ISO/IEC 27001:2013

OncoKDM® relies on an ISO 27001 certified infrastructure. The underlying information security management system of this certification facilitates the compliance with the GDPR through the implementation of the necessary technical and organizational measures to ensure the integrity, confidentiality and appropriate security of your personal data, including their protection against unauthorized or illegal treatment, and their loss, destruction or accidental damage.

HIPAA COMPLIANT

HIPAA (Health Insurance Portability and Accountability Act of 1996) is a United States legislation that provides data privacy and security provisions for safeguarding medical information.
In healthcare circles, adhering to HIPAA requires healthcare organizations to implement secure electronic access to health data and to remain in compliance with privacy regulations.

Read more on OncoKDM® HIPAA compliancy on www.oncodna.com/en/compliancy

LIVE SUPPORT

Should you have any requests or questions, OncoKDM® is giving you access to our scientific support team through the live chat feature.



ONCOKDM (LITE OFFER) FEATURES

- ✓ VCF files upload
- ✓ Clinical information
- ✓ SNV / InDel interpretation
- ✓ Variants classification (biological/therapeutical impact)
- ✓ Drugs recommendations
- ✓ Clinical trials (II, III, IV) matcher
- ✓ Bibliography
- ✓ Downloadable (pdf) comprehensive report
- ✓ Editable and shareable comprehensive report

CONTACT US

OncoDNA

OncoDNA is a cancer theranostic company that uses a combination of the most relevant molecular technologies to support oncologists in their treatment decisions for patients.

OncoDNA S.A.
Rue Louis Breguet 1,
6041 Gosselies,
Belgium

+32 (0) 71 18 35 00
infos@oncodna.com

OncoKDM®

TO SUPPORT ONCOLOGISTS IN THEIR TREATMENT DECISION BY PROVIDING THE BEST CLINICAL RECOMMENDATIONS

The Clinical Decision Support for Oncology

FAST • SMART • EASY

www.oncokdm.com

What is OncoKDM® (Lite offer)

OncoKDM® (Lite offer) is a commercial offer based on OncoKDM®, a web-based Clinical Decision Support (CDS) expert system that translates NGS somatic variants into actionable clinical insight enabling oncologists to provide patients with personalised treatments based on:

- Variants classification according to clinical guidelines
- Drugs and clinical trials available related to your data and patient condition
- Real world evidences based on OncoDNA diagnostic activity
- Relied on public information curated by OncoDNA's scientific experts



KNOWLEDGEBASE

OncoKDM® interacts with our proprietary database.

Our proprietary database (OncoKDO) is enriched weekly with new information by our algorithms and expert scientists. On top of that, it is daily feed by real world data and real-world evidences coming from OncoDNA's diagnostic activity:

*Public data sources: Pub Med literature, CLinVar, COSMIC, GnomAD, OncoKB, Clinicaltrials.gov,...

PROCESS

1. SAMPLE FILES UPLOAD AND PATIENT CASE SETTING
Upload VCF files, set your analysis parameters and launch the interpretation process in few clicks.

2. INSERTION/DELETIONS/SNV CLINICAL INTERPRETATION
OncoKDM® BioIT process filters and interprets complex insertions and deletions (indels) from NGS somatic data as well as single nucleotide variations (SNV).

3. VARIANTS CLASSIFICATION
Biological and therapeutical (TIER) variants classification in line with clinical guidelines.

4. CLINICAL INTERPRETATION: THERAPIES AND CLINICAL TRIALS MATCH
Accordingly to our proprietary database and actionable variants, the app provides patient-specific drugs recommandations and clinical trials.

How it works

SAMPLE FILES UPLOAD AND PATIENT CASE SETTING

Import VCF files generated by the variant calling pipeline, create your patient cases, set your analyses parameters and launch the interpretation in few clicks.

VCF import was tested and validated with the most common variant calling software (Pisces / TorrentServerVariantCaller / freebayes / GATK: HaplotypeCaller / VarScan / Samtools: BcFtools (https://github.com/samtools/bcftools) / Mutect1 / Platypus / CLCBio / Mutect2 / VarDict / NextGene / LoFreq.

Panel agnostic

Because OncoKDM is panel agnostic, whatever you are using a focus or a comprehensive panel (TSO500), if your genes come from the 595 most common genes used for molecular profiling in oncology, the platform will perform a complete tertiary interpretation pathologists and oncologists can use during the molecular board.

BRAND	PANEL
Illumina	AmpliSeq for Illumina Cancer Hotspot Panel V2, AmpliSeq for Illumina Comprehensive Panel V3, AmpliSeq for Illumina Focus Panel, TruSight Tumor 170, TruSight Tumor 15, TruSight Oncology 500
Ion Torrent	OncoMINE Focus Assay, OncoMINE Comprehensive Assay
Qiagen	Breast cancer Panel, Human Colorectal cancer Panel, Human Lung cancer Panel, Human Actionable Solid Tumor Panel
Agilent	ClearSeq Comprehensive Cancer Panel
ArcherDX	Any panel starting from the VCF files

Patient's clinical information and follow-up

Because patient's assessment is required to provide with the best interpretation, both **"patient information"** and **"follow-up"** panels allow clinicians to set patient's condition and history.

INSERTIONS / DELETIONS / SNV CLINICAL INTERPRETATION

OncoKDM® BioIT process filters and interprets complex insertions and deletions (indels) from the NGS somatic data as well as single nucleotide variations (SNV).

Gene	Drugs Related To Gene	Cat.	Variant Frequency	cDNA Variant	Amino Acid Variant	Biological Impact	Therapeutical Impact	Drugs Related To Patient
EGFR	6	INS	39 %	c.2309_2310insACACCCCC	p.H773_V774dup	Pathogenic	Tier I	6

INSERTION
Reference sequence : AATTGTG - AGAAGCTGGAG
Insertion variant : AATTGTG T AGAAGCTGGAG

DELETION
Reference sequence : AATTGTG A GAAGCTGGAG
Deletion variant : AATTGTG - GAAGCTGGAG

SNV
Reference sequence : AATTGTG A GAAGCTGGAG
Insertion variant : AATTGTG G AGAAGCTGGAG

ROUTINE CLINICAL PROCESS

VARIANTS CLASSIFICATION

Thanks to curated sources and proprietary algorithms, filtered variants are classified following clinical guidelines (ACMG, COMPERMED,...) including biological and therapeutical impacts:

Gene	Drugs Related To Gene	Cat.	Variant Frequency	cDNA Variant	Amino Acid Variant	Biological Impact	Therapeutical Impact	Drugs Related To Patient
EGFR	6	INS	39 %	c.2309_2310insACACCCCC	p.H773_V774dup	Pathogenic	Tier I	6

BIOLOGICAL CLASSES*

CLASSIFICATION
Pathogenic
Probably pathogenic
Variants of Unknown Significance
Probably Benign
Benign

CLINICAL (THERAPEUTICAL) CLASSES*

TIER	CLASSIFICATION (therapeutic, prognostic, diagnostic)
I	Strong Clinical Significance
II	Potential Clinical Significance
III	Variants of Unknown Significance
IV	Likely Benign / Benign

* This classification is based on the ACMG and AMP Standards and Guidelines publication of Richards et al. Genet Med 2015, even though these guidelines are meant for germline variants.

* This classification is based on the ACMG and AMP Standards and Guidelines publication of Li et al. J Mol Diagn 2017.

THERAPIES AND CLINICAL TRIALS MATCH

Based on clear and scientifically validated evidences OncoKDM® proprietary algorithm will report relevant FDA/EMA drugs classified by clinical benefit relevance and geolocalised clinical trials.